NO20053185L - Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. - Google Patents

Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Info

Publication number
NO20053185L
NO20053185L NO20053185A NO20053185A NO20053185L NO 20053185 L NO20053185 L NO 20053185L NO 20053185 A NO20053185 A NO 20053185A NO 20053185 A NO20053185 A NO 20053185A NO 20053185 L NO20053185 L NO 20053185L
Authority
NO
Norway
Prior art keywords
treatment
hyperactivity disorder
attention
failure
attention failure
Prior art date
Application number
NO20053185A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053185D0 (no
Inventor
Jr Vincent Edward Groppi
Donn Gregory Wishka
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20053185D0 publication Critical patent/NO20053185D0/no
Publication of NO20053185L publication Critical patent/NO20053185L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
NO20053185A 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. NO20053185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11
PCT/IB2003/005542 WO2004052461A1 (en) 2002-12-11 2003-11-28 Combination for the treatment of adhd

Publications (2)

Publication Number Publication Date
NO20053185D0 NO20053185D0 (no) 2005-06-29
NO20053185L true NO20053185L (no) 2005-08-17

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053185A NO20053185L (no) 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Country Status (23)

Country Link
US (1) US20050107425A1 (es)
EP (1) EP1572300A1 (es)
JP (1) JP2006510663A (es)
KR (1) KR20050085538A (es)
CN (1) CN1735441A (es)
AP (1) AP2005003336A0 (es)
AU (1) AU2003283656A1 (es)
BR (1) BR0317229A (es)
CA (1) CA2509142A1 (es)
CO (1) CO5700801A2 (es)
CR (1) CR7868A (es)
EA (1) EA200500783A1 (es)
EC (1) ECSP055852A (es)
HR (1) HRP20050522A2 (es)
IS (1) IS7858A (es)
MA (1) MA27606A1 (es)
MX (1) MXPA05006336A (es)
NO (1) NO20053185L (es)
OA (1) OA12969A (es)
PL (1) PL377552A1 (es)
TN (1) TNSN05158A1 (es)
WO (1) WO2004052461A1 (es)
ZA (1) ZA200504338B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MX2010009110A (es) * 2008-02-19 2010-11-30 Adolor Corp Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor.
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
SI3029039T1 (en) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス， インコーポレイテッド 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
WO2023022256A1 (ko) 2021-08-19 2023-02-23 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
EP4389126A1 (en) 2021-08-20 2024-06-26 Dankook University Cheonan Campus Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
AP2005003336A0 (en) 2005-06-30
KR20050085538A (ko) 2005-08-29
TNSN05158A1 (fr) 2007-05-14
CO5700801A2 (es) 2006-11-30
CR7868A (es) 2005-07-08
EP1572300A1 (en) 2005-09-14
EA200500783A1 (ru) 2005-12-29
MXPA05006336A (es) 2005-08-26
CA2509142A1 (en) 2004-06-24
AU2003283656A1 (en) 2004-06-30
OA12969A (en) 2006-10-13
BR0317229A (pt) 2005-11-01
CN1735441A (zh) 2006-02-15
JP2006510663A (ja) 2006-03-30
ECSP055852A (es) 2005-09-20
NO20053185D0 (no) 2005-06-29
US20050107425A1 (en) 2005-05-19
PL377552A1 (pl) 2006-02-06
WO2004052461A1 (en) 2004-06-24
IS7858A (is) 2005-05-23
HRP20050522A2 (en) 2005-12-31
ZA200504338B (en) 2006-07-26
MA27606A1 (fr) 2005-11-01

Similar Documents

Publication Publication Date Title
NO20053185L (no) Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.
NL301145I2 (nl) Tirbanibulin
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
NO20100077L (no) Behandling med alfa7-selektive ligander
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
BRPI0515376A (pt) método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação
DE60323091D1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
WO2006012476A3 (en) Method for treating nervous system disorders and conditions
DK1575590T3 (da) Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
DE602005010258D1 (de) Behandlung von ballastwasser
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
DE60223390D1 (de) Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
NO20081200L (no) Polyalkyleniminer og polyalkylenakrylamidsalt for syregass scrubbingprosess
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
MX2008007418A (es) Uso de las microesferas de carbono adsorbentes para el tratamiento del síndrome de intestino irritable.